372 related articles for article (PubMed ID: 32664581)
1. Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma.
Ferri A; Stagni V; BarilĂ D
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664581
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma.
Gil del Alcazar CR; Hardebeck MC; Mukherjee B; Tomimatsu N; Gao X; Yan J; Xie XJ; Bachoo R; Li L; Habib AA; Burma S
Clin Cancer Res; 2014 Mar; 20(5):1235-48. PubMed ID: 24366691
[TBL] [Abstract][Full Text] [Related]
3. C1q/TNF-related peptide 8 (CTRP8) promotes temozolomide resistance in human glioblastoma.
Thanasupawat T; Glogowska A; Burg M; Krcek J; Beiko J; Pitz M; Zhang GJ; Hombach-Klonisch S; Klonisch T
Mol Oncol; 2018 Sep; 12(9):1464-1479. PubMed ID: 29949238
[TBL] [Abstract][Full Text] [Related]
4. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.
Middleton FK; Patterson MJ; Elstob CJ; Fordham S; Herriott A; Wade MA; McCormick A; Edmondson R; May FE; Allan JM; Pollard JR; Curtin NJ
Oncotarget; 2015 Oct; 6(32):32396-409. PubMed ID: 26486089
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.
Zhou M; Sareddy GR; Li M; Liu J; Luo Y; Venkata PP; Viswanadhapalli S; Tekmal RR; Brenner A; Vadlamudi RK
Sci Rep; 2019 Apr; 9(1):6124. PubMed ID: 30992459
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
[TBL] [Abstract][Full Text] [Related]
7. ATM inhibition exploits checkpoint defects and ATM-dependent double strand break repair in TP53-mutant glioblastoma.
Laverty DJ; Gupta SK; Bradshaw GA; Hunter AS; Carlson BL; Calmo NM; Chen J; Tian S; Sarkaria JN; Nagel ZD
Nat Commun; 2024 Jun; 15(1):5294. PubMed ID: 38906885
[TBL] [Abstract][Full Text] [Related]
8. Glioblastoma recurrent cells switch between ATM and ATR pathway as an alternative strategy to survive radiation stress.
Kaur E; Ketkar M; Dutt S
Med Oncol; 2022 Feb; 39(5):50. PubMed ID: 35150325
[TBL] [Abstract][Full Text] [Related]
9. Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide.
Eich M; Roos WP; Nikolova T; Kaina B
Mol Cancer Ther; 2013 Nov; 12(11):2529-40. PubMed ID: 23960094
[TBL] [Abstract][Full Text] [Related]
10. Breaking the DNA damage response to improve cervical cancer treatment.
Wieringa HW; van der Zee AG; de Vries EG; van Vugt MA
Cancer Treat Rev; 2016 Jan; 42():30-40. PubMed ID: 26643553
[TBL] [Abstract][Full Text] [Related]
11. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
[TBL] [Abstract][Full Text] [Related]
12. Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma.
Gil Del Alcazar CR; Todorova PK; Habib AA; Mukherjee B; Burma S
Mol Cancer Res; 2016 Oct; 14(10):928-940. PubMed ID: 27358111
[TBL] [Abstract][Full Text] [Related]
13. Targeting the AKT pathway in glioblastoma.
McDowell KA; Riggins GJ; Gallia GL
Curr Pharm Des; 2011; 17(23):2411-20. PubMed ID: 21827416
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of miR-1193 leads to synthetic lethality in glioblastoma multiforme cells deficient of DNA-PKcs.
Zhang J; Jing L; Tan S; Zeng EM; Lin Y; He L; Hu Z; Liu J; Guo Z
Cell Death Dis; 2020 Jul; 11(7):602. PubMed ID: 32732911
[TBL] [Abstract][Full Text] [Related]
15. The DNA damage/repair cascade in glioblastoma cell lines after chemotherapeutic agent treatment.
Annovazzi L; Caldera V; Mellai M; Riganti C; Battaglia L; Chirio D; Melcarne A; Schiffer D
Int J Oncol; 2015; 46(6):2299-308. PubMed ID: 25892134
[TBL] [Abstract][Full Text] [Related]
16. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
[TBL] [Abstract][Full Text] [Related]
17. Molecular pathways and potential therapeutic targets in glioblastoma multiforme.
Wardak Z; Choe KS
Expert Rev Anticancer Ther; 2013 Nov; 13(11):1307-18. PubMed ID: 24168050
[TBL] [Abstract][Full Text] [Related]
18. DNA end-processing enzyme polynucleotide kinase as a potential target in the treatment of cancer.
Allinson SL
Future Oncol; 2010 Jun; 6(6):1031-42. PubMed ID: 20528239
[TBL] [Abstract][Full Text] [Related]
19. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
[TBL] [Abstract][Full Text] [Related]
20. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]